Elektrofi
Greg DeFilippis has a diverse range of experience in business development and alliance management. Greg currently serves as the Chief Business Officer at Elektrofi since February 2023. Prior to that, they worked at Halozyme, Inc. as the Senior Vice President and Chief Business Officer, where they were responsible for strategic leadership, business development, and licensing. Greg managed Halozyme's partnerships and development programs from May 2022 to December 2022. Before joining Halozyme, Greg held various roles at Antares Pharma Inc., including Senior Vice President of Device Business and Alliances, Vice President of Business Development and Alliances, and Senior Director of Business Alliances and Device Supply Chain Management. Greg played a significant role in the growth of the company and the acquisition by Halozyme. Greg also has experience in business development at Teva Pharmaceuticals and Barr Pharmaceuticals. Greg began their career at Alpharma as a Lean Six Sigma Master Black Belt.
Greg DeFilippis has a Bachelor of Science (B.S.) degree in Industrial & Systems Engineering from Virginia Tech. Greg also holds a Master of Business Administration (M.B.A.) degree in Finance from Fairleigh Dickinson University. Furthermore, Greg has completed a program in Strategic Negotiations at Harvard Business School and a course in Lean Six Sigma as a Lean Six Sigma Master Black Belt at the Six Sigma Academy.
This person is not in any offices
Elektrofi
1 followers
Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and frequency of dosing. Elektrofi partners with pharmaceutical companies to jointly develop patient-friendly delivery solutions. Headquartered in Boston, the company’s founding team of MIT engineers and scientists are shaping the future of biologics delivery.